JP2018517757A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018517757A5 JP2018517757A5 JP2017565967A JP2017565967A JP2018517757A5 JP 2018517757 A5 JP2018517757 A5 JP 2018517757A5 JP 2017565967 A JP2017565967 A JP 2017565967A JP 2017565967 A JP2017565967 A JP 2017565967A JP 2018517757 A5 JP2018517757 A5 JP 2018517757A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- disease
- inducer
- administered
- inducing agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000001939 inductive effect Effects 0.000 claims 11
- 239000003443 antiviral agent Substances 0.000 claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 239000000411 inducer Substances 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 108010067390 Viral Proteins Proteins 0.000 claims 5
- 102000006601 Thymidine Kinase Human genes 0.000 claims 4
- 108020004440 Thymidine kinase Proteins 0.000 claims 4
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 3
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 3
- 230000003612 virological effect Effects 0.000 claims 3
- 206010011831 Cytomegalovirus infection Diseases 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 206010015108 Epstein-Barr virus infection Diseases 0.000 claims 2
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 claims 2
- 102000001253 Protein Kinase Human genes 0.000 claims 2
- WPVFJKSGQUFQAP-GKAPJAKFSA-N Valcyte Chemical compound N1C(N)=NC(=O)C2=C1N(COC(CO)COC(=O)[C@@H](N)C(C)C)C=N2 WPVFJKSGQUFQAP-GKAPJAKFSA-N 0.000 claims 2
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 claims 2
- 229960004150 aciclovir Drugs 0.000 claims 2
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229960002963 ganciclovir Drugs 0.000 claims 2
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 229940127073 nucleoside analogue Drugs 0.000 claims 2
- 229960001179 penciclovir Drugs 0.000 claims 2
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 claims 2
- 108060006633 protein kinase Proteins 0.000 claims 2
- 229960002149 valganciclovir Drugs 0.000 claims 2
- KPQFKCWYCKXXIP-XLPZGREQSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(methylamino)pyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(NC)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 KPQFKCWYCKXXIP-XLPZGREQSA-N 0.000 claims 1
- WVXRAFOPTSTNLL-NKWVEPMBSA-N 2',3'-dideoxyadenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO)O1 WVXRAFOPTSTNLL-NKWVEPMBSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 claims 1
- 208000016937 Extranodal nasal NK/T cell lymphoma Diseases 0.000 claims 1
- 208000009889 Herpes Simplex Diseases 0.000 claims 1
- 208000029433 Herpesviridae infectious disease Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
- 229930010555 Inosine Natural products 0.000 claims 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims 1
- 102100034343 Integrase Human genes 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims 1
- 206010057269 Mucoepidermoid carcinoma Diseases 0.000 claims 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 206010030216 Oesophagitis Diseases 0.000 claims 1
- 108700020796 Oncogene Proteins 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 206010035742 Pneumonitis Diseases 0.000 claims 1
- 229940123066 Polymerase inhibitor Drugs 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 1
- 108700020978 Proto-Oncogene Proteins 0.000 claims 1
- 102000052575 Proto-Oncogene Human genes 0.000 claims 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims 1
- 206010037779 Radiculopathy Diseases 0.000 claims 1
- 206010038910 Retinitis Diseases 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 claims 1
- 101710172711 Structural protein Proteins 0.000 claims 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 claims 1
- 206010058874 Viraemia Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 229960000684 cytarabine Drugs 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 229960002656 didanosine Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- -1 edoxdine Chemical compound 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 208000006881 esophagitis Diseases 0.000 claims 1
- 229960004396 famciclovir Drugs 0.000 claims 1
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 claims 1
- 229960000961 floxuridine Drugs 0.000 claims 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 claims 1
- 229960005102 foscarnet Drugs 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 206010066435 human herpesvirus 8 infection Diseases 0.000 claims 1
- 229960004716 idoxuridine Drugs 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229960003786 inosine Drugs 0.000 claims 1
- 229940124524 integrase inhibitor Drugs 0.000 claims 1
- 239000002850 integrase inhibitor Substances 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 229960001627 lamivudine Drugs 0.000 claims 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 208000006473 polyradiculopathy Diseases 0.000 claims 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 229960000329 ribavirin Drugs 0.000 claims 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 230000002103 transcriptional effect Effects 0.000 claims 1
- 208000009174 transverse myelitis Diseases 0.000 claims 1
- 229960003962 trifluridine Drugs 0.000 claims 1
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 claims 1
- 229960003636 vidarabine Drugs 0.000 claims 1
- 229960000523 zalcitabine Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021211486A JP2022058416A (ja) | 2015-06-19 | 2021-12-24 | ヘルペスウイルス誘発疾患の処置のための方法および組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562182071P | 2015-06-19 | 2015-06-19 | |
| US62/182,071 | 2015-06-19 | ||
| PCT/US2016/038148 WO2016205695A1 (en) | 2015-06-19 | 2016-06-17 | Methods and compositions for treating herpesvirus induced conditions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021211486A Division JP2022058416A (ja) | 2015-06-19 | 2021-12-24 | ヘルペスウイルス誘発疾患の処置のための方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018517757A JP2018517757A (ja) | 2018-07-05 |
| JP2018517757A5 true JP2018517757A5 (enExample) | 2019-07-18 |
| JP7366385B2 JP7366385B2 (ja) | 2023-10-23 |
Family
ID=57546411
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017565967A Active JP7366385B2 (ja) | 2015-06-19 | 2016-06-17 | ヘルペスウイルス誘発疾患の処置のための方法および組成物 |
| JP2021211486A Pending JP2022058416A (ja) | 2015-06-19 | 2021-12-24 | ヘルペスウイルス誘発疾患の処置のための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021211486A Pending JP2022058416A (ja) | 2015-06-19 | 2021-12-24 | ヘルペスウイルス誘発疾患の処置のための方法および組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US20180185345A1 (enExample) |
| EP (1) | EP3310168B1 (enExample) |
| JP (2) | JP7366385B2 (enExample) |
| CN (2) | CN108347929A (enExample) |
| WO (1) | WO2016205695A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| CN109715173A (zh) | 2016-07-15 | 2019-05-03 | 维拉克塔治疗公司 | 供基于nk细胞的疗法使用的hdac抑制剂 |
| US20230190756A1 (en) * | 2017-12-08 | 2023-06-22 | Boris Farber | Pharmaceutical formulation for the elimination of causative agents of herpesviral infections from the tissues of a macroorganism |
| JP7194458B2 (ja) | 2018-07-19 | 2022-12-22 | 国立大学法人大阪大学 | ウイルス計測方法、ウイルス計測装置、およびストレス判定装置 |
| PH12021552997A1 (en) * | 2019-05-31 | 2023-08-14 | Viracta Subsidiary Inc | Methods of treating virally associated cancers with histone deacetylase inhibitors |
| AR119033A1 (es) * | 2019-05-31 | 2021-11-17 | Viracta Therapeutics Inc | Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa |
| CN114306364B (zh) * | 2019-07-18 | 2023-06-16 | 北京市农林科学院 | 盐酸吉西他滨和吉西他滨在抑制犬细小病毒中的应用 |
| CN112294810B (zh) * | 2019-07-29 | 2024-03-01 | 深圳微芯生物科技股份有限公司 | 含有西达本胺和表面活性剂的药物组合物 |
| TW202110444A (zh) * | 2019-08-28 | 2021-03-16 | 大陸商深圳微芯生物科技股份有限公司 | 一種西達本胺藥物組合物及其製備方法和用途 |
| CN112569243A (zh) * | 2019-09-30 | 2021-03-30 | 神农医药科技有限公司 | 制备治疗阿尔茨海默病的药物 |
| JP2022552642A (ja) * | 2019-10-07 | 2022-12-19 | ヴィラクタ サブシディアリー，インク． | 副作用が軽減されたｈｄａｃ治療の調剤 |
| CN111187751A (zh) * | 2020-01-19 | 2020-05-22 | 中国农业科学院兰州兽医研究所 | 一种用于构建幼畜心肌炎细胞模型的细胞系及构建方法 |
| CN112111006B (zh) * | 2020-08-27 | 2022-06-07 | 北京弘进久安生物科技有限公司 | 抗牛结节性皮肤病病毒的抗体、检测试纸及试剂盒 |
| EP4232076A1 (en) * | 2020-10-20 | 2023-08-30 | The Chancellor, Masters and Scholars of The University of Oxford | Methods and compositions for treating epstein barr virus-associated cancer |
| CN112980878B (zh) * | 2021-02-04 | 2023-03-31 | 中国农业科学院兰州兽医研究所 | Hdac8基因敲除的bhk-21细胞系及其构建方法和应用 |
| CN112877275B (zh) * | 2021-02-04 | 2023-03-31 | 中国农业科学院兰州兽医研究所 | Hdac2基因敲除的bhk-21细胞系及其构建方法和应用 |
| WO2023190843A1 (ja) | 2022-03-31 | 2023-10-05 | 住友重機械工業株式会社 | 支援装置、作業機械、プログラム |
| WO2023244968A1 (en) * | 2022-06-13 | 2023-12-21 | Viracta Subsidiary, Inc. | Methods of treating autoimmune disorders with histone deacetylase inhibitors |
| EP4622714A1 (en) * | 2022-11-21 | 2025-10-01 | Henderson, Theodore | Treatment using an antiviral compound and spironolactone |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4747825A (en) | 1984-06-29 | 1988-05-31 | Ferring Laboratories, Inc. | Apparatus and methodology for pulsed administration of growth promoting agents |
| US4948592A (en) | 1986-05-09 | 1990-08-14 | Alza Corporation | Pulsed drug delivery |
| US4723958A (en) | 1986-05-23 | 1988-02-09 | Merck & Co., Inc. | Pulsatile drug delivery system |
| US4965251A (en) | 1987-04-03 | 1990-10-23 | The Board Of Regents Of The University Of Washington | Pulse treatment of hemoglobinopathies with erythropoietin |
| US5766573A (en) | 1988-12-06 | 1998-06-16 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
| US5190029A (en) | 1991-02-14 | 1993-03-02 | Virginia Commonwealth University | Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content |
| US5376359A (en) | 1992-07-07 | 1994-12-27 | Glaxo, Inc. | Method of stabilizing aerosol formulations |
| US5403590A (en) | 1992-12-21 | 1995-04-04 | New England Deaconess Hospital Corporation | Method of pulsatile drug infusion |
| WO2011038224A1 (en) * | 2009-09-24 | 2011-03-31 | Trustees Of Boston University | Methods for treating viral disorders |
| WO2011113013A2 (en) * | 2010-03-11 | 2011-09-15 | Hemaquest Pharmaceuticals, Inc. | Methods and compositions for treating viral or virally-induced conditions |
| EP2755648B1 (en) * | 2011-09-13 | 2017-03-08 | Pharmacyclics LLC | Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof |
| US9415070B2 (en) * | 2012-11-09 | 2016-08-16 | Massachusetts Institute Of Technology | Methods and compositions for localized delivery of agents to virally infected cells and tissues |
| CN104083763A (zh) | 2014-07-16 | 2014-10-08 | 中国人民解放军军事医学科学院野战输血研究所 | 组蛋白去乙酰化酶抑制剂在制备潜伏病毒激活剂中的应用 |
-
2016
- 2016-06-17 EP EP16812548.2A patent/EP3310168B1/en active Active
- 2016-06-17 CN CN201680046420.0A patent/CN108347929A/zh active Pending
- 2016-06-17 CN CN202310699709.4A patent/CN116712552A/zh active Pending
- 2016-06-17 JP JP2017565967A patent/JP7366385B2/ja active Active
- 2016-06-17 WO PCT/US2016/038148 patent/WO2016205695A1/en not_active Ceased
- 2016-06-17 US US15/737,701 patent/US20180185345A1/en not_active Abandoned
-
2020
- 2020-03-30 US US16/835,122 patent/US20210046061A1/en not_active Abandoned
-
2021
- 2021-12-24 JP JP2021211486A patent/JP2022058416A/ja active Pending
-
2023
- 2023-06-07 US US18/206,947 patent/US20240041848A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018517757A5 (enExample) | ||
| Razonable | Antiviral drugs for viruses other than human immunodeficiency virus | |
| de Clercq | Milestones in the discovery of antiviral agents: nucleosides and nucleotides | |
| US20250114389A1 (en) | Nucleosides and nucleotides analogs as antiviral agents | |
| US20190022116A1 (en) | N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto | |
| JP2019526562A (ja) | Ｈｂｖキャプシドアセンブリ阻害剤とヌクレオシ（チ）ド類似体の併用療法 | |
| Schang | Effects of pharmacological cyclin-dependent kinase inhibitors on viral transcription and replication | |
| JP2019068829A5 (enExample) | ||
| US20190083520A1 (en) | N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto | |
| AR079555A1 (es) | Metodos de tratamiento de la infeccion de virus de hepatitis b (hbv) y virus de hepatitis c (hcv) | |
| Radetskyy et al. | ADAR1 and PKR, interferon stimulated genes with clashing effects on HIV-1 replication | |
| IL273681B1 (en) | Enantiomers of thiazoles are converted as antiviral compounds | |
| CN114533739B (zh) | 核苷类似物在制备预防或治疗胃肠道疾病药物中的应用 | |
| CA2287370A1 (en) | Synthesis, anti-human immunodeficiency virus and anti-hepatitis b virus activities of 1,3-oxaselenolane nucleosides | |
| De Clercq | Curious discoveries in antiviral drug development: The role of serendipity | |
| US20140017336A1 (en) | Co-administration of arsenic compounds and anti-herpes virus anti-virals | |
| JP5326173B2 (ja) | エプスタイン・バールウイルス関連疾患に対する薬剤およびそのスクリーニング法 | |
| EG et al. | A review on therapeutic potential of heterocyclic pyrimidine derivatives as potent antiviral agents | |
| WO2022160323A1 (zh) | 核苷类似物在制备预防或治疗胃肠道疾病药物中的应用 | |
| Colgan et al. | Antiviral drugs in the immunocompetent host: part I. Treatment of hepatitis, cytomegalovirus, and herpes infections | |
| Myrcludex | Newer drugs for the treatment of hepatitis B viral infection | |
| Ohrui | A new paradigm for developing antiviral drugs exemplified by the development of supremely high anti-HIV active EFdA | |
| CN117017991A (zh) | Hdac6选择性抑制剂在制备慢性乙型病毒性肝炎抗病毒治疗药物中的应用 | |
| Wang et al. | Anti-hepatitis B virus drugs in clinical and preclinical development | |
| ÇETİNKAYA et al. | DRUGS USED IN THE TREATMENT OF VIRAL INFECTIONS AND INNOVATIONS IN ANTIVIRAL THERAPY1 |